


Searching News Database: P2045
HSMN NewsFeed - 3 Jun 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
HSMN NewsFeed - 6 Sep 2006
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin
